Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating

Core Insights - Evolus, Inc. (NASDAQ:EOLS) has had its price target lowered by Mizuho analyst Uy Ear from $19 to $15 while maintaining an Outperform rating, indicating confidence in the company's long-term growth despite a weaker-than-expected fourth quarter [1] - The company reported a revenue of $69 million for the third quarter of 2025, reflecting a 13% year-over-year growth, driven by strong demand for its products Jeuveau and Evolysse [3] - Evolus focuses on injectable aesthetic treatments in the cash-pay market and aims to expand its international presence while building a differentiated portfolio of physician-led brands [4] Financial Performance - The revenue of Evolus for the third quarter of 2025 was $69 million, marking a 13% increase compared to the previous year [3] - The growth is attributed to sustained global demand for Jeuveau and the U.S. launch of Evolysse, showcasing the company's ability to diversify its revenue streams [3] Company Strategy - Evolus is positioning itself for continued market share gains by expanding its product portfolio and international footprint [4] - The company was founded in 2012 and is headquartered in Newport Beach, California, indicating a relatively young but strategically focused operation in the performance beauty sector [4]